Loading
FT
Filana Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$34M
1 insider bought €313k of shares over the last 90 days, the latest filed 01 Oct 2026.
Filana Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Filana Therapeutics, Inc. as filed with SEC (Form 4). The group dates from 1998. Between 18 October 2025 and 18 October 2026, 2 insiders published 6 filings.
Only purchases show up on the open market, 6 purchases in all worth €868k, filed by 2 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. One trade stands out by size: a purchase of €359k from Barry Richard, disclosed on 24 November 2025. Those buying include 1 senior executive and 1 chief executive.
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last insider purchase was made public on 1 October 2026, 17 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4.
Compared with its exchange (5,458 companies, median 22 filings), a count of 6 filings is below the norm. Our records for Filana Therapeutics, Inc. go back to 2021, with 16 purchases and 1 sale on the open market in total.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
39
Thresholds
n/a
Buy Volume
€5M
16 ops. · all time
Sell Volume
€14,655
1 ops. · all time
Who traded when
BuySaleRichard Barry7 buys
James William Kupiec1 sale
Robert Christopher Cook1 buy
Robert Eugene Anderson Jr.1 buy
Since the insiders bought
- -27.7%Entry US$3.39 · Close at T+90 US$2.45
- -28.9%Entry US$3.04 · Close at T+90 US$2.16
- -76.0%Entry US$3.63 · Close at T+365 US$0.87
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.70
Analyst consensus
2 analysts1.50/5
US$5.00Target US$6.50(+824%)US$8.00
Income statement
RevenueUS$36.3M
EBITDA-US$95.2M-262% margin
Net income-US$91M0.0% margin
Valuation
P/Book0.5x
Beta-0.66
Balance sheet & cash
Market capUS$34M
Free Cash Flow-US$32.8M
Profitability & ownership
ROE-55.8%
ROA-7.1%
% insiders2.0%
% institutions26.8%
Last declaration on 1 October 2026
Declarations39 total
206,813 shares@ US$0.9052.2% of flowCommon StockSEC:0001437749-26-031654:0
Canonical exit: 28 Dec 2026 (T+90)
100,000 shares@ US$0.9225.9% of flowCommon StockSEC:0001437749-26-031654:1
Canonical exit: 29 Dec 2026 (T+90)
93,091 shares@ US$0.84100.0% of flowCommon StockSEC:0001437749-26-031597:0
Canonical exit: 27 Dec 2026 (T+90)
8,600 shares@ US$2.90100.0% of flowCommon StockSEC:0001437749-25-036321:0
Canonical exit: 22 Feb 2026 (T+90)
150,000 shares@ US$2.766.7% of flowCommon StockSEC:0001437749-25-036125:0
Canonical exit: 18 Feb 2026 (T+90)
73,385 shares@ US$2.753.3% of flowCommon StockSEC:0001437749-25-035882:0
Canonical exit: 17 Feb 2026 (T+90)
13,725 shares@ US$2.91100.0% of flowCommon StockSEC:0001437749-25-030348:0
Canonical exit: 29 Dec 2025 (T+90)
7,172 shares@ US$2.280.3% of flowCommon StockSEC:0001437749-25-029725:0
Canonical exit: 21 Dec 2025 (T+90)
5,400 shares@ US$2.130.2% of flowCommon StockSEC:0001437749-25-029586:0
Canonical exit: 17 Dec 2025 (T+90)
4,000 shares@ US$3.8713.7% of flowCommon StockSEC:0001437749-24-036551:0
50,000 shares@ US$1.1841.3% of flowCommon StockSEC:0001437749-24-036546:0
5,000 shares0Common StockSEC:0001437749-24-017355:0
69,000 shares@ US$22.0034.4% of flowCommon StockSEC:0001437749-24-013866:0
176,085 shares@ US$22.0067.6% of flowCommon StockSEC:0001437749-24-013144:0
1,500 shares@ US$22.0029.0% of flowCommon StockSEC:0001437749-24-012643:0
1,500 shares@ US$22.0022.9% of flowCommon StockSEC:0001437749-24-012331:0
30,000 shares@ US$17.4511.7% of flowCommon StockSEC:0001069530-23-000045:0
Canonical exit: 21 Nov 2023 (T+90)
1,906 shares@ US$16.800.5% of flowCommon StockSEC:0001069530-23-000043:0
Canonical exit: 19 Nov 2023 (T+90)
1,000 shares@ US$0.95100.0% of flowCommon StockSEC:0001069530-23-000037:0
14,285 shares@ US$16.874.0% of flowCommon StockSEC:0001069530-23-000035:0
3,571 shares@ US$19.601.5% of flowCommon StockSEC:0001069530-23-000033:0
2,142 shares@ US$16.6617.8% of flowCommon StockSEC:0001069530-23-000019:0
3,571 shares@ US$16.66100.0% of flowCommon StockSEC:0001069530-23-000013:0
11,565 shares@ US$26.135.3% of flowCommon StockSEC:0001069530-23-000011:0
Canonical exit: 4 Jun 2023 (T+90)
9,376 shares@ US$0.9510.6% of flowCommon StockSEC:0001069530-22-000049:0
25 of 39 declarations
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc. is a company focused on developing innovative therapies for serious diseases. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
